Stock listing
KRX:302440 SK bioscience Co.,Ltd. (SK바이오사이언스) 주가
Follow SK bioscience Co.,Ltd. into a list and get an email when it puts out news.
Share price · KRX:302440
₩38,500 KRW +300 (+0.8%)
Close on Nov 20, 2026
- Day range
- ₩37,400 – ₩39,050 KRWNov 20, 2026
- Volume
- 77,747 sharesNov 20, 2026
- Market cap
- ₩3.02T KRWAt the close on Nov 20, 2026 · price × 78.46M shares outstanding
- 52-week range
- ₩31,500 – ₩55,700 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩3.25B KRWMedian day 73,352 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:302440 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩38,500 | +300 | +0.8% | ₩37,550 | ₩39,050 | ₩37,400 | 77,747 | |
| ₩38,200 | -1,700 | -4.3% | ₩39,450 | ₩40,100 | ₩38,200 | 98,969 | |
| ₩39,900 | +600 | +1.5% | ₩39,500 | ₩41,450 | ₩39,250 | 127,589 | |
| ₩39,300 | +300 | +0.8% | ₩39,250 | ₩40,250 | ₩38,800 | 54,627 | |
| ₩39,000 | -450 | -1.1% | ₩38,800 | ₩40,050 | ₩38,800 | 65,093 | |
| ₩39,450 | -500 | -1.3% | ₩39,900 | ₩40,400 | ₩38,450 | 114,498 | |
| ₩39,950 | +250 | +0.6% | ₩39,800 | ₩41,550 | ₩39,350 | 107,143 | |
| ₩39,700 | -700 | -1.7% | ₩39,950 | ₩41,700 | ₩39,000 | 138,359 | |
| ₩40,400 | +2,000 | +5.2% | ₩38,250 | ₩42,950 | ₩38,200 | 510,374 | |
| ₩38,400 | +1,450 | +3.9% | ₩35,450 | ₩39,700 | ₩35,200 | 204,513 | |
| ₩36,950 | +2,450 | +7.1% | ₩35,200 | ₩37,300 | ₩35,200 | 135,104 | |
| ₩34,500 | +1,300 | +3.9% | ₩33,250 | ₩34,500 | ₩32,850 | 98,043 | |
| ₩33,200 | -50 | -0.2% | ₩33,400 | ₩33,450 | ₩32,100 | 174,588 | |
| ₩33,250 | +500 | +1.5% | ₩32,300 | ₩33,700 | ₩32,200 | 44,185 | |
| ₩32,750 | +550 | +1.7% | ₩32,500 | ₩33,250 | ₩31,850 | 87,076 | |
| ₩32,200 | +50 | +0.2% | ₩32,150 | ₩32,550 | ₩31,550 | 55,704 | |
| ₩32,150 | +400 | +1.3% | ₩32,000 | ₩32,750 | ₩32,000 | 65,710 | |
| ₩31,750 | -250 | -0.8% | ₩32,150 | ₩32,700 | ₩31,700 | 73,074 | |
| ₩32,000 | -1,150 | -3.5% | ₩32,800 | ₩33,150 | ₩31,500 | 94,907 | |
| ₩33,150 | -1,450 | -4.2% | ₩34,400 | ₩34,900 | ₩33,000 | 81,409 | |
| ₩34,600 | -850 | -2.4% | ₩35,350 | ₩35,600 | ₩34,550 | 54,112 | |
| ₩35,450 | -350 | -1.0% | ₩36,150 | ₩36,750 | ₩35,400 | 72,210 | |
| ₩35,800 | -1,200 | -3.2% | ₩36,500 | ₩37,550 | ₩35,650 | 59,676 | |
| ₩37,000 | +700 | +1.9% | ₩36,200 | ₩37,150 | ₩35,650 | 75,544 | |
| ₩36,300 | +950 | +2.7% | ₩35,250 | ₩37,250 | ₩35,200 | 83,722 | |
| ₩35,350 | -950 | -2.6% | ₩36,100 | ₩36,150 | ₩34,800 | 83,971 | |
| ₩36,300 | -150 | -0.4% | ₩36,550 | ₩36,950 | ₩35,700 | 58,189 | |
| ₩36,450 | 0 | 0.0% | ₩35,600 | ₩36,500 | ₩34,750 | 97,339 | |
| ₩36,450 | -300 | -0.8% | ₩36,850 | ₩37,450 | ₩36,150 | 69,609 | |
| ₩36,750 | -1,250 | -3.3% | ₩37,450 | ₩37,500 | ₩36,750 | 87,838 | |
| ₩38,000 | +750 | +2.0% | ₩38,250 | ₩38,750 | ₩37,500 | 82,432 | |
| ₩37,250 | +750 | +2.1% | ₩36,700 | ₩37,800 | ₩36,650 | 66,392 | |
| ₩36,500 | -300 | -0.8% | ₩37,100 | ₩37,150 | ₩36,050 | 46,272 | |
| ₩36,800 | +700 | +1.9% | ₩36,400 | ₩37,200 | ₩36,150 | 62,553 | |
| ₩36,100 | +200 | +0.6% | ₩36,100 | ₩36,450 | ₩35,550 | 48,212 | |
| ₩35,900 | -550 | -1.5% | ₩36,400 | ₩36,400 | ₩35,450 | 49,953 | |
| ₩36,450 | +700 | +2.0% | ₩35,750 | ₩36,850 | ₩35,500 | 68,610 | |
| ₩35,750 | 0 | 0.0% | ₩35,550 | ₩36,100 | ₩35,450 | 59,220 | |
| ₩35,750 | +100 | +0.3% | ₩35,800 | ₩36,150 | ₩35,500 | 51,840 | |
| ₩35,650 | +500 | +1.4% | ₩35,350 | ₩36,050 | ₩35,200 | 53,334 | |
| ₩35,150 | -1,100 | -3.0% | ₩36,600 | ₩36,800 | ₩35,150 | 103,032 | |
| ₩36,250 | +50 | +0.1% | ₩36,400 | ₩36,575 | ₩36,000 | 41,435 | |
| ₩36,200 | -550 | -1.5% | ₩36,350 | ₩36,800 | ₩35,850 | 55,079 | |
| ₩36,750 | -1,050 | -2.8% | ₩37,350 | ₩37,800 | ₩36,600 | 63,476 | |
| ₩37,800 | +550 | +1.5% | ₩36,900 | ₩38,150 | ₩36,850 | 69,063 | |
| ₩37,250 | -750 | -2.0% | ₩37,000 | ₩37,850 | ₩36,950 | 53,864 | |
| ₩38,000 | +700 | +1.9% | ₩36,800 | ₩38,000 | ₩36,650 | 97,021 | |
| ₩37,300 | +550 | +1.5% | ₩36,700 | ₩37,350 | ₩36,400 | 54,490 | |
| ₩36,750 | -850 | -2.3% | ₩37,800 | ₩38,100 | ₩36,750 | 64,129 | |
| ₩37,600 | -300 | -0.8% | ₩38,150 | ₩38,150 | ₩37,500 | 65,260 | |
| ₩37,900 | +150 | +0.4% | ₩38,050 | ₩38,150 | ₩37,650 | 46,060 | |
| ₩37,750 | +300 | +0.8% | ₩37,500 | ₩39,050 | ₩37,200 | 81,339 | |
| ₩37,450 | -900 | -2.3% | ₩37,750 | ₩38,200 | ₩37,400 | 73,629 | |
| ₩38,350 | -50 | -0.1% | ₩38,700 | ₩38,900 | ₩38,000 | 63,567 | |
| ₩38,400 | -550 | -1.4% | ₩38,450 | ₩38,900 | ₩37,450 | 75,323 | |
| ₩38,950 | +500 | +1.3% | ₩38,300 | ₩38,950 | ₩38,000 | 57,833 | |
| ₩38,450 | +350 | +0.9% | ₩37,900 | ₩38,650 | ₩37,750 | 81,128 | |
| ₩38,100 | +550 | +1.5% | ₩37,900 | ₩38,250 | ₩37,050 | 85,009 | |
| ₩37,550 | -750 | -2.0% | ₩37,750 | ₩37,800 | ₩36,400 | 87,866 | |
| ₩38,300 | +1,800 | +4.9% | ₩37,500 | ₩38,500 | ₩37,150 | 106,982 | |
| ₩36,500 | -1,250 | -3.3% | ₩36,800 | ₩37,000 | ₩35,750 | 73,765 | |
| ₩37,750 | +1,950 | +5.4% | ₩38,200 | ₩39,150 | ₩37,100 | 183,719 |
- Ticker
- KRX:302440
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Mar 18, 2026
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
Latest news
SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support
Mar 18, 2026
Closed ₩41,950 (-3.6%) on Mar 19, 2026
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
Feb 26, 2026
Closed ₩48,950 (-1.8%) on Feb 27, 2026
SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute
Feb 3, 2026
Closed ₩49,000 (-1.8%) on Feb 4, 2026
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
Jan 28, 2026
Closed ₩51,500 (0.0%) on Jan 29, 2026
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
Jan 22, 2026
Closed ₩51,500 (+4.6%) on Jan 23, 2026
SK bioscience Co.,Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 14 in all · newest Mar 18, 2026 · oldest 2025
Valuation
EV/sales 4.1× against a median of 19.6×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩2.72T KRW
- P/E
- Loss
- EV/sales
- 4.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- 14.3%
- Operating margin
- −19.9%
- Net margin
- −12.8%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.26B | US$2.03B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| Keymed Biosciences, Inc. · HKEX:2162 | US$2.43B | US$2.04B | n/a | 19.6× | n/a | 4.0× | −73.0% | 0.2× | n/a |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.70B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.8M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.00B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Median of the others | US$2.20B | US$1.71B | 108× | 19.6× | 90.0× | 4.1× | −73.9% | 0.0× | 1.39 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 36200.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- -829.50 · 1 analyst
- Revenue, year to Dec 2026
- 714.6B · 5 analysts
Events
- Next results
- Feb 3, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 · Before open | −1.3% |
| Q2 2026 | Aug 13, 2026 · Before open | +1.0% |
| Q1 2026 | May 13, 2026 · Before open | −1.6% |
| Q4 2025 | Mar 13, 2026 · Before open | +0.7% |
| Q3 2025 | Nov 13, 2025 | −1.6% |
| Q2 2025 | Aug 12, 2025 · Before open | −0.7% |
| Q1 2025 | May 14, 2025 · Before open | +0.5% |
| Q4 2024 | Feb 5, 2025 · Before open | +2.1% |
| Q3 2024 | Nov 13, 2024 · Before open | −3.0% |
| Q2 2024 | Aug 13, 2024 · Before open | −2.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −0.7% |
| Q4 2023 | Feb 1, 2024 · Before open | +0.9% |
| Q3 2023 | Oct 26, 2023 · Before open | −1.0% |
| Q2 2023 | Jul 28, 2023 · Before open | −3.1% |
| Q1 2023 | Apr 27, 2023 · Before open | −0.8% |
| Q4 2022 | Mar 3, 2023 · Before open | +5.5% |
| Q3 2022 | Nov 14, 2022 · Before open | +3.5% |
| Q2 2022 | Aug 12, 2022 · Before open | +2.4% |
| Q1 2022 | May 13, 2022 · Before open | +2.1% |
| Q4 2021 | Feb 7, 2022 · Before open | −2.6% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 651.4B | 267.5B | 369.5B | 456.7B | 929.0B | 225.6B | 183.9B | 88.2B |
| Cost of revenue | 575.4B | 236.6B | 227.3B | 217.1B | 358.7B | 130.3B | 110.9B | 49.0B |
| Gross profit | 75.9B | 31.0B | 142.2B | 239.6B | 570.3B | 95.3B | 79.6B | 39.2B |
| Research and development | 69.9B | 71.4B | 85.7B | 58.0B | 47.3B | 26.0B | 27.7B | 10.5B |
| Selling, general and administrative | 48.2B | 40.9B | 25.3B | 27.3B | 15.7B | 12.8B | 12.6B | 7.04B |
| Operating income | -123.5B | -138.4B | -12.0B | 115.0B | 474.2B | 37.7B | 6.47B | 15.2B |
| Depreciation and amortization | 91.0B | 49.2B | 34.8B | 27.2B | 18.8B | 16.5B | 14.5B | 6.59B |
| EBITDA | -32.5B | -89.2B | 22.8B | 142.3B | 493.0B | 54.2B | 21.0B | 21.8B |
| Interest expense | 9.40B | 3.68B | 1.40B | 2.46B | 3.43B | 4.15B | 3.95B | 2.42B |
| Income before tax | -85.9B | -89.1B | 7.33B | 141.7B | 471.1B | 37.3B | 18.5B | 864.0M |
| Income tax | 116.0B | 4.40B | ||||||
| Net income | -57.4B | -53.9B | 22.3B | 122.5B | 355.1B | 32.9B | 14.7B | 420.8M |
| Earnings per share, basic | -732.13 | -701.32 | 290.49 | 1,594.76 | 4,642.34 | 537.41 | 239.83 | 6.88 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 105.6B | 312.7B | 127.0B | 225.3B | 98.0B | 25.0B | 14.4B | 4.49B |
| Short-term investments | 800.7B | 845.4B | 1.15T | 1.26T | 1.55T | 183.7B | 80.1B | 99.2B |
| Receivables | 122.0B | 94.5B | 12.9B | 39.6B | 38.0B | 30.5B | 32.2B | 42.9B |
| Inventory | 189.2B | 211.1B | 80.6B | 187.4B | 135.0B | 70.3B | 36.4B | 31.9B |
| Current assets | 1.25T | 1.58T | 1.38T | 1.78T | 1.84T | 333.9B | 170.7B | 180.7B |
| Property, plant and equipment | 221.0B | 189.5B | ||||||
| Goodwill | 55.3B | 57.4B | ||||||
| Total assets | 2.96T | 2.84T | 1.85T | 2.14T | 2.11T | 562.2B | 404.0B | 402.7B |
| Accounts payable | 35.3B | 17.8B | 3.37B | 11.1B | 63.8B | 17.5B | 18.4B | 11.1B |
| Current liabilities | 326.2B | 310.6B | 135.6B | 380.0B | 460.0B | 180.6B | 45.5B | 61.8B |
| Long-term debt | 464.7B | 383.3B | 35.5B | 102.2B | 116.6B | 125.8B | ||
| Total liabilities | 918.3B | 821.1B | 148.6B | 400.2B | 508.8B | 298.4B | 171.2B | 192.0B |
| Shareholders' equity | 1.79T | 1.80T | 1.70T | 1.74T | 1.60T | 263.8B | 232.7B | 210.7B |
| Shares outstanding | 78.4M | 76.8M | 76.8M | 76.8M | 76.5M | 61.2M | 61.2M | 61.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 102.5B | -128.0B | 29.3B | -125.0B | 536.6B | 120.2B | 21.8B | 14.9B |
| Capital spending | -260.4B | -172.2B | -50.3B | -76.5B | -42.9B | -9.93B | -24.0B | -6.31B |
| Free cash flow | -157.9B | -300.2B | -20.9B | -201.4B | 492.1B | 110.0B | -4.04B | 8.59B |
| Cash from investing | -1.42T | -108.1B | ||||||
| Cash from financing | 958.4B | -1.54B | ||||||
| Change in cash | -207.1B | 185.7B | -98.3B | 127.3B | 73.1B | 10.6B | 9.89B | -1.90B |
Cap table
Built by 6ix from SK bioscience Co.,Ltd.’s releases
- Common shares
- 78,456,553
- Fully diluted
- 78,456,553
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 78,456,553 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 78,456,553 |
Log in to ask 6ix AI your own questions about SK bioscience Co.,Ltd.